Biotech entity
pharma is the sole category represented across all 1 tracked stories. Swami S. Iyer is most often covered alongside Aurobindo Pharma Ltd., which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Swami S. Iyer, all published on July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Swami S. Iyer is most often covered alongside Aurobindo Pharma Ltd., which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Swami S. Iyer, all published on July 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Swami S. Iyer. Shared-story counts are live from our verified record — not editorial picks.
FTC Approval Granted
The U.S. Federal Trade Commission approved Aurobindo Pharma USA’s $250 million acquisition of Lannett Company LLC, clearing the final regulatory hurdle.
Aurobindo Pharma’s US subsidiary receives FTC clearance for its $250 million cash-free acquisition of Lannett, adding a complex generics and controlled substances portfolio expected to be immediately accretive to EPS and generate significant synergies.
Source: moneycontrol.com · economictimes.indiatimes.com
Swami S. Iyer is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
